Total Revenue: $203 million, up 3% year-over-year. Prescription Transactions Revenue: Increased by 2% year-over-year. Manufacturer Solutions Revenue: Increased by 17% year-over-year. Adjusted EBITDA: $69.8 million, up 11% year-over-year. Adjusted EBITDA Margin: 34.4%, an improvement of 60 basis points from the previous quarter. Cash and …
Revenue Growth: 4% year-over-year, with 3% organic growth. Gross Profit Growth: 4% year-over-year, with 2% organic growth. Gross Margin: 34%. Adjusted EBITDA Margin: 13%. Adjusted EBITDA Growth: 8% organic year-over-year. Cash Conversion: 50% over the last 12 months. Cash Flow from Operations: Negative SEK104 …
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Airtel Africa PLC (AAFRF) reported strong constant currency revenue growth of over 23% in Q4, up from 19% in Q1. The …
We recently published an article titled Billionaire Steve Cohen's 10 Mid-Cap Stock Picks with Huge Upside Potential.In this article, we are going to take a look at where Twilio Inc. (NYSE:TWLO) stands against Steve Cohen's other mid-cap stock picks with huge upside potential. Steven …
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Autohome Inc (NYSE:ATHM) achieved a 72.6% year-over-year increase in revenues from new energy vehicles (NEVs), including their new retail business. The …
Total Revenue Growth: 8% at constant currency. Coach Revenue Growth: 15% increase. International Revenue Growth: 8% increase, with Europe up 35%. North America Revenue Growth: 9% increase. Greater China Revenue Growth: 5% increase. Gross Margin: 76.1%, highest in over 15 years, up 140 basis …
We recently published an article titled Billionaire Steve Cohen's 10 Mid-Cap Stock Picks with Huge Upside Potential.In this article, we are going to take a look at where PG&E Corporation (NYSE:PCG) stands against Steve Cohen's other mid-cap stock picks with huge upside potential. Steven …
Revenue: DKK8 million for Q1 2025, primarily from the license and development agreement for Zegalogue with Novo Nordisk. Research and Development Expenses: DKK290 million, driven by the development of petrelintide and related trials. Sales and Marketing Expenses: DKK37 million, mainly for pre-commercial activities related …
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BCE Inc (NYSE:BCE) announced a major partnership with PSP Investments, which will help fund their U.S. fiber business with commitments exceeding …
Post-pay Net Additions: 262,000, up nearly 50,000 from a year ago. Home Net Additions: 62,000, compared to a decline of 13,000 in Q1 last year. OCF Margin: Increased by almost 2 percentage points to 36.7%. Equity Free Cash Flow: $135 million in Q1. Leverage: …